BR112013023167A2 - método para produção do fator viii humano recombinante, fator viii humano recombinante, produto farmacêutico, uso do fator viii humano recombinante, método para tratamento de doenças relacionadas à diminuição, inativação ou ausência de fator viii, uso da endoprotease spc6 e/ou da pace4 ai e/ou da pacesol e processamento proteolítico do fator viii humano recombinante - Google Patents

método para produção do fator viii humano recombinante, fator viii humano recombinante, produto farmacêutico, uso do fator viii humano recombinante, método para tratamento de doenças relacionadas à diminuição, inativação ou ausência de fator viii, uso da endoprotease spc6 e/ou da pace4 ai e/ou da pacesol e processamento proteolítico do fator viii humano recombinante

Info

Publication number
BR112013023167A2
BR112013023167A2 BR112013023167A BR112013023167A BR112013023167A2 BR 112013023167 A2 BR112013023167 A2 BR 112013023167A2 BR 112013023167 A BR112013023167 A BR 112013023167A BR 112013023167 A BR112013023167 A BR 112013023167A BR 112013023167 A2 BR112013023167 A2 BR 112013023167A2
Authority
BR
Brazil
Prior art keywords
factor viii
recombinant human
human factor
proteolytic processing
pacesol
Prior art date
Application number
BR112013023167A
Other languages
English (en)
Inventor
Christian Colin
Marcos Angelo Almeida Demasi
Mari Cleide Sogayar
Original Assignee
Univ São Paulo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ São Paulo filed Critical Univ São Paulo
Publication of BR112013023167A2 publication Critical patent/BR112013023167A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6454—Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21826—Proprotein convertase 5 (3.4.21.B26)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo método para produção do fator viii humano recombinante a presente invenção tem por objeto métodos para produção de fator viii humano recombinante, que empregam endoproteases específicas, garantindo o processamento proteolítico completo deste fator ainda durante sua biossíntese e, conseqüentemente, evitando etapas adicionais de purificação. são ainda objetos da presente invenção o fator viii humano recombinante obtido por tais métodos, composições farmacêuticas, usos e métodos terapêuticos relacionados.
BR112013023167A 2011-03-11 2011-03-11 método para produção do fator viii humano recombinante, fator viii humano recombinante, produto farmacêutico, uso do fator viii humano recombinante, método para tratamento de doenças relacionadas à diminuição, inativação ou ausência de fator viii, uso da endoprotease spc6 e/ou da pace4 ai e/ou da pacesol e processamento proteolítico do fator viii humano recombinante BR112013023167A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/BR2011/000069 WO2012122611A1 (en) 2011-03-11 2011-03-11 Method for the production of recombinant human factor viii

Publications (1)

Publication Number Publication Date
BR112013023167A2 true BR112013023167A2 (pt) 2016-09-06

Family

ID=46829968

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013023167A BR112013023167A2 (pt) 2011-03-11 2011-03-11 método para produção do fator viii humano recombinante, fator viii humano recombinante, produto farmacêutico, uso do fator viii humano recombinante, método para tratamento de doenças relacionadas à diminuição, inativação ou ausência de fator viii, uso da endoprotease spc6 e/ou da pace4 ai e/ou da pacesol e processamento proteolítico do fator viii humano recombinante

Country Status (3)

Country Link
US (1) US20140051832A1 (pt)
BR (1) BR112013023167A2 (pt)
WO (1) WO2012122611A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3508573A1 (en) 2010-07-09 2019-07-10 Bioverativ Therapeutics Inc. Systems for factor viii processing and methods thereof
AU2015234611A1 (en) * 2014-03-23 2016-11-10 Advantech Bioscience Farmaceutica Ltda. Enhancement of recombinant protein expression with copper
WO2015149143A2 (en) 2014-04-01 2015-10-08 Advantech Bioscience Farmacêutica Ltda. Stable factor viii formulations with low sugar-glycine
AU2015240354A1 (en) 2014-04-01 2016-11-17 Advantech Bioscience Farmaceutica Ltda. Stabilization of Factor VIII without calcium as an excipient

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2096418C (en) * 1990-11-26 2001-11-20 Philip J. Barr Expression of pace in host cells and methods of use thereof
US5965789A (en) * 1991-01-11 1999-10-12 American Red Cross Engineering protein posttranslational modification by PACE/furin in transgenic non-human mammals
CA2078721A1 (en) * 1991-09-24 1993-03-25 Hiroshi Yonemura Process for preparing human coagulation factor viii protein complex
US6596526B1 (en) * 2000-06-09 2003-07-22 Baxter Aktiengesellschaft Furin polypeptides with improved characteristics
WO2008022151A1 (en) * 2006-08-15 2008-02-21 Inspiration Biopharmaceuticals, Inc. Prophylactic treatment of hemophilia
JP5727790B2 (ja) * 2007-12-27 2015-06-03 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 細胞培養プロセス
DK2240578T3 (da) * 2007-12-31 2019-06-17 Baxalta GmbH I alt væsentligt dyreproteinfrit rekombinant furin og fremgangsmåder til fremstilling af samme

Also Published As

Publication number Publication date
WO2012122611A1 (en) 2012-09-20
US20140051832A1 (en) 2014-02-20

Similar Documents

Publication Publication Date Title
MX2018010427A (es) Formas solidas de un inhibidor de tienopirimidindiona acetil coa carboxilasa y metodos para su produccion.
TN2014000131A1 (en) Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives, process for preparation thereof, pharmaceutical preparations comprising them, and use thereof for production of medicaments
BR112015021495A2 (pt) fabricação contínua integrada de substâncias de droga de proteína terapêutica
BR112017004704A2 (pt) composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio em um indivíduo
BR112012020953A2 (pt) produto, uso do mesmo, metodo para prevencao e/ou tratamento de fibrose corneana ou opacidade corneana e composicao farmaceutica oftalmica
PH12014501984A1 (en) Pharmaceutical compositions comprising metformin and a dpp-4 inhibitor or a sglt-2 inhibitor
UA113729C2 (xx) Мутантний поліпептид інтерлейкіну-2 (il-2)
PH12015500106A1 (en) Novel 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof
UA116999C2 (uk) Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить
WO2016024205A8 (en) Oligomers targeting hexanucleotide repeat expansion in human c9orf72 gene
BR112013022789A2 (pt) composições farmacêuticas que compreendem metformina e um inibidor dpp-4 ou um inibidor sglt-2
UY32919A (es) Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
MX340500B (es) Inhibidores selectivos y reversibles de la proteasa específica de ubiquitina 7.
PA8784001A1 (es) Oxazolidinonas sustituidas y su uso
BR112013001753A2 (pt) método para preparar uma composição d einter-alfa-inibidor (iaip) eriquecida de plasma, solução aquosa de iaip, e, método para tratar uma doença ou distúrbio associado com disfunção de iaip e associado com atividadede protease de serina no plasma aumentada.
EA200801580A1 (ru) Новые производные пирониндола и способ их получения
CL2008002394A1 (es) Depsipeptido ciclico, o derivados, inhibidores de calicreína 7, obtenidos desde chondromyces crocatus, metodo de obtencion y usos terapeuticos.
MX2016000794A (es) Composiciones farmaceuticas de pancreatina de potencia alta.
BR112014027981A2 (pt) compostos do tipo fumagilol e métodos de produção e utilização dos mesmos
TN2015000007A1 (en) 3-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments
CU20110215A7 (es) Piperidinas sustituidas
MX2016000480A (es) Composiciones farmaceuticas de pancreatina de alta potencia.
MX2018002318A (es) Proceso mejorado para producir fucoxantina y/o polisacaridos de microalgas.
BR112013023167A2 (pt) método para produção do fator viii humano recombinante, fator viii humano recombinante, produto farmacêutico, uso do fator viii humano recombinante, método para tratamento de doenças relacionadas à diminuição, inativação ou ausência de fator viii, uso da endoprotease spc6 e/ou da pace4 ai e/ou da pacesol e processamento proteolítico do fator viii humano recombinante
MX2020009566A (es) Compuestos como moduladores de la se?alizacion de tlr2.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]